FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899447277> ?p ?o ?g. }

• W2899447277 endingPage "35622" @default.
• W2899447277 startingPage "35611" @default.
• W2899447277 abstract "// Joshua N. Kellner 1 , Eveline M. Delemarre 2 , Eric Yvon 3 , Stefan Nierkens 2 , Jaap J. Boelens 4 , Ian McNiece 3 , Amanda Olson 3 , Yago Nieto 3 , Stefan Ciurea 3 , Uday Popat 3 , Sairah Ahmed 3 , Richard Champlin 3 , Jennifer Ramos 3 , Mitsutaka Nishimoto 5 , Hongbing Ma 5 , Zeng Ke 5 , Peter Thall 6 , Joseph D. Khoury 7 , Robert Negrin 8 , Borje Andersson 3 and Simrit Parmar 1, 5 1 Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Laboratory of Translational Immunology, University Medical Center Utrecht, Heidelberglaan, CX Utrecht, The Netherlands 3 Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Department of Pediatrics, Stem Cell Transplant and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, NY, USA 5 Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA 6 Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA 7 Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA 8 Division of Blood and Marrow Transplantation, Stanford University, Palo Alto, CA, USA Correspondence to: Simrit Parmar, email: sparmar@mdanderson.org Keywords: regulatory T cells; umbilical cord blood; graft versus host disease; cell therapy; stem cell transplantation Received: August 19, 2018      Accepted: October 06, 2018      Published: November 02, 2018 ABSTRACT Incubation of umbilical cord blood (UCB) derived regulatory T-cells (Tregs) with fucosyltransferase enzyme improves their ability to home to the target tissue to prevent graft vs. host disease (GVHD). We report results of 5 patients (Double UCB Transplant, n=2; Peripheral Blood Matched Unrelated Donor Transplant, n=3) who received UCB-Tregs (Dose level = 1×106/kg), infused one day prior to the donor graft. All patients received their designated UCB-Treg dose without any infusion reaction. The ratio of conventional T-cells in donor graft was at least 10 times higher than infused UCB-Tregs (ratio range, 12-356). All patients engrafted at median of 13 days (range, 8-17 days). One patient died due to brain hemorrhage on day 45. A bi-modal increase of plasma IL-10 level occurred on day 7 and day 21 and notably, plasma IL-2 level dropped significantly in all patients at Day 7. All evaluable patients developed ≥grade II acute GVHD and at 1 year follow up, all were alive and without evidence of disease relapse. No increase in the chronic GVHD biomarkers (REG3a and Elafin) was observed at day 7. At the time of last follow up, all evaluable patients were off immune-suppression. Stage 2 of this clinical trial examining UCB-Treg at dose level= 1×107/kg is currently underway." @default.
• W2899447277 created "2018-11-09" @default.
• W2899447277 creator A5001390394 @default.
• W2899447277 creator A5002347804 @default.
• W2899447277 creator A5004417292 @default.
• W2899447277 creator A5005492422 @default.
• W2899447277 creator A5006002552 @default.
• W2899447277 creator A5016915045 @default.
• W2899447277 creator A5026422612 @default.
• W2899447277 creator A5029237145 @default.
• W2899447277 creator A5031211693 @default.
• W2899447277 creator A5035361443 @default.
• W2899447277 creator A5038451446 @default.
• W2899447277 creator A5039574726 @default.
• W2899447277 creator A5048913229 @default.
• W2899447277 creator A5066320639 @default.
• W2899447277 creator A5066894053 @default.
• W2899447277 creator A5067252491 @default.
• W2899447277 creator A5081543404 @default.
• W2899447277 creator A5082887496 @default.
• W2899447277 creator A5086290087 @default.
• W2899447277 creator A5088881526 @default.
• W2899447277 creator A5091083304 @default.
• W2899447277 date "2018-11-02" @default.
• W2899447277 modified "2023-09-29" @default.
• W2899447277 title "Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution" @default.
• W2899447277 cites W1981428999 @default.
• W2899447277 cites W1981690705 @default.
• W2899447277 cites W1986741896 @default.
• W2899447277 cites W1998795836 @default.
• W2899447277 cites W2010486962 @default.
• W2899447277 cites W2043711686 @default.
• W2899447277 cites W2049774501 @default.
• W2899447277 cites W2058551818 @default.
• W2899447277 cites W2072274685 @default.
• W2899447277 cites W2073045132 @default.
• W2899447277 cites W2076668534 @default.
• W2899447277 cites W2078660478 @default.
• W2899447277 cites W2090807791 @default.
• W2899447277 cites W2104497593 @default.
• W2899447277 cites W2138839197 @default.
• W2899447277 cites W2154320959 @default.
• W2899447277 cites W2170074551 @default.
• W2899447277 cites W2337931770 @default.
• W2899447277 cites W2529012154 @default.
• W2899447277 cites W2573156932 @default.
• W2899447277 cites W2586256617 @default.
• W2899447277 cites W2745616170 @default.
• W2899447277 cites W2766122872 @default.
• W2899447277 cites W2809164184 @default.
• W2899447277 cites W4246682656 @default.
• W2899447277 doi "https://doi.org/10.18632/oncotarget.26242" @default.
• W2899447277 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6235025" @default.
• W2899447277 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30479692" @default.
• W2899447277 hasPublicationYear "2018" @default.
• W2899447277 type Work @default.
• W2899447277 sameAs 2899447277 @default.
• W2899447277 citedByCount "25" @default.
• W2899447277 countsByYear W28994472772019 @default.
• W2899447277 countsByYear W28994472772020 @default.
• W2899447277 countsByYear W28994472772021 @default.
• W2899447277 countsByYear W28994472772022 @default.
• W2899447277 countsByYear W28994472772023 @default.
• W2899447277 crossrefType "journal-article" @default.
• W2899447277 hasAuthorship W2899447277A5001390394 @default.
• W2899447277 hasAuthorship W2899447277A5002347804 @default.
• W2899447277 hasAuthorship W2899447277A5004417292 @default.
• W2899447277 hasAuthorship W2899447277A5005492422 @default.
• W2899447277 hasAuthorship W2899447277A5006002552 @default.
• W2899447277 hasAuthorship W2899447277A5016915045 @default.
• W2899447277 hasAuthorship W2899447277A5026422612 @default.
• W2899447277 hasAuthorship W2899447277A5029237145 @default.
• W2899447277 hasAuthorship W2899447277A5031211693 @default.
• W2899447277 hasAuthorship W2899447277A5035361443 @default.
• W2899447277 hasAuthorship W2899447277A5038451446 @default.
• W2899447277 hasAuthorship W2899447277A5039574726 @default.
• W2899447277 hasAuthorship W2899447277A5048913229 @default.
• W2899447277 hasAuthorship W2899447277A5066320639 @default.
• W2899447277 hasAuthorship W2899447277A5066894053 @default.
• W2899447277 hasAuthorship W2899447277A5067252491 @default.
• W2899447277 hasAuthorship W2899447277A5081543404 @default.
• W2899447277 hasAuthorship W2899447277A5082887496 @default.
• W2899447277 hasAuthorship W2899447277A5086290087 @default.
• W2899447277 hasAuthorship W2899447277A5088881526 @default.
• W2899447277 hasAuthorship W2899447277A5091083304 @default.
• W2899447277 hasBestOaLocation W28994472771 @default.
• W2899447277 hasConcept C121608353 @default.
• W2899447277 hasConcept C126322002 @default.
• W2899447277 hasConcept C143998085 @default.
• W2899447277 hasConcept C203014093 @default.
• W2899447277 hasConcept C2776955114 @default.
• W2899447277 hasConcept C2777408962 @default.
• W2899447277 hasConcept C2780914630 @default.
• W2899447277 hasConcept C28328180 @default.
• W2899447277 hasConcept C2911091166 @default.
• W2899447277 hasConcept C54355233 @default.
• W2899447277 hasConcept C71924100 @default.
• W2899447277 hasConcept C86803240 @default.

• next